This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1116 entries already.
Positive Phase 3 results with Sanofi/Regeneron’s IL4/IL-13-targeting antibody dupilumab (Dupixent) in adolescents with moderate-to-severe atopic dermatitis will form the basis of a regulatory submission in this new patient population, according to announcements of […]
Slowing the leak of Calcium leak into cardiomyocytes does not improve the pumping malfunction in heart failure, German cardiologists report in Science Translational Medicine.
EMBL Ventures has announced that its portfolio company ViraTherapeutics is set to be acquired by Boehringer Ingelheim in a 210m million (US$245m) transaction.
Orphan drug leader Shire plc has been granted EU marketing authorization for its recombinant van Willebrand factor (rVWF) vonicog alfa as second-line treatment for van Willebrand disease, the most common […]
Drug Developers dealing with PD1-PDL1 checkpoint inhibitors must consider new safety problems associated with the hyped cancer meds.
The European Investment Bank (EIB) has issued its first Sustainability Awareness Bond worth 500m to support investments into water projects – health and nutrition to follow.
Around 300 international AMR experts met at ESCMID-ASM drug development conference in Lisbon to discuss the latest progress in the field.
Oxford-based Adaptimmune Therapeutics plc has raised US$100m in a registered direct offering of American Depositary Shares (ADS).
The NHS England announces it will reimburse Novartis CAR-T cell therapy Kymriah as treatment for children with B cell acute lymphoblastic leukemia (ALL) that are refractory, in relapse post-transplant or […]
Exosome drug delivery specialist Evox Therapeutics Ltd has closed a 37.1m (£35.5m) Series B financing round led by Redmile Group and significant contributions from GV (Google Ventures) and Cowen Healthcare Investments.